cyrilzakka/clinical-trials huggingface dataset:
A Multicentre Study to Explore the Efficacy and Safety of Mucopolysaccharide Polysulfate Cream in Patients With Eczema

The study was designed to collect information over 1800 patients with a clinical diagnosis of subacute or chronic eczema, these patients' prescriptions contain Hirudoid®. EASI, IGA and more indicators are evaluated. Data were collected for a maximum of 12 weeks according to the clinician's consultation and follow-up (Time points were set at baseline, 1, 2, 3, 4, 8 and 12 weekends). The above data were analysed to explore the optimal treatment modality, dose and treatment period for patients with subacute or chronic eczema.

The study was designed to collect information over 1800 patients with a clinical diagnosis of subacute or chronic eczema, these patients' prescriptions contain Hirudoid® (Hirudoid® alone or in combination with glucocorticoids). Basic demographic information (age, sex, height, weight, lifestyle, occupation), vital signs (blood pressure, heart rate, temperature, etc.), past medical and treatment history, eczema area and severity index (EASI) scores and corresponding symptom scores, Dermatology Life Quality Index (DLQI) score, Investigator's global assessment (IGA) of disease severity score, Visual analogue scale (VAS) with subject's pruritus, photographs of the eczema area and recurrence rate were collected. Data were evaluated for a maximum of 12 weeks according to the clinician's consultation and follow-up (Time points were set at baseline, 1, 2, 3, 4, 8 and 12 weekends). The above data were analysed to explore the optimal treatment modality, dose and treatment period for patients with subacute or chronic eczema.

Eligibility Criteria:
Inclusion Criteria:

1. 18-75 years of age, male or female;.
2. Patients with a clinical diagnosis of subacute or chronic eczema and whose prescription contains Hirudoid®.
3. Subjects fully understand the content of this study, sign informed consent.

Exclusion Criteria:

1. Hypersensitivity to any of the ingredients of this product.
2. Patients with heparin hypersensitivity, bleeding-prone constitution and known heparin-induced thrombocytopenia.
3. Open wounds and broken skin and mucous membranes
4. Patients with localized combined bacterial, viral and fungal infections.
5. Pregnant or lactating women or those who are unable to use contraception during the study period
6. Those with psychiatric disorders, poor compliance and unable to complete the study.
7. Any other reason that the investigator considers inappropriate for inclusion.
Telerehabilitation Approaches in Chronic Obstructive Pulmonary Patients

Pulmonary rehabilitation (PR) is a first-line management strategy in chronic obstructive pulmonary patients (COPD) as it reduces shortness of breath, increases exercise capacity, and improves health-related quality of life. However, 8-50% of patients referred to PR do not participate at all, while 10-32% of those who start do not complete the program. Barriers to participation and completion include difficulty in accessing the program, poor mobility, lack of transport, and travel costs. Telerehabilitation is defined as the provision of rehabilitation services through telecommunication technology, including telephone, internet and video conference communications between the patient and the healthcare provider. Different technologies (from phone to video conferencing) have been tested in patients with COPD to enhance daily activities, exercise training and walking prescription. All of them showed positive effects on exercise tolerance, dyspnea, physical activity and quality of life. However, there is no study about which telerehabilitation program is more effective on COPD patients. The aim of this study is to investigate which telerehabilitation approach is more effective in COPD.


Eligibility Criteria:
Inclusion Criteria:

* Being diagnosed with COPD (FEV1 / FVC \<70% in the stable phase of the disease)
* Age \> 18 years old
* Have the ability to use a smartphone

Exclusion Criteria:

* Musculoskeletal disorders that limit exercise
* Dizziness, significant sensory or motor impairments, dementia or terminal illnesses that prevent education
* Serious comorbidities such as unstable heart disease, irregular diabetes, known malignant disease, any other disease that makes the patient unsuitable for participation in the study.
* Incompatible patient
* Severe vision or hearing impairment
* Unwillingness or inability to follow the protocol
* Have had a COPD exacerbation in the previous 6 weeks
A Multicenter Clinical Study of rTMS for Parkinson's Disease

Through rTMS, motor dysfunction and non-motor dysfunction of PD patients can be improved, working and living ability and quality of life of patients can be improved, and social burden and family burden can be reduced.

According to the inclusion criteria, a total of 200 patients with Parkinson's disease were planned to be enrolled in each center, and randomly divided into control group (conventional treatment) and observation group (conventional treatment +rTMS) for a treatment cycle of 4 weeks. They were followed up for 3 months before treatment, 2 weeks and 4 weeks, respectively, after treatment, to evaluate the efficacy and function. The unified Parkinson's Disease Rating Scale (UPDRS) was used. Cognitive function assessment Monteller Cognitive Assessment Scale (MoCA); Barthel Index for daily living activities; Depression assessment Hamilton Depression Scale (HAMD); Hamilton Anxiety Scale (HAMA); Sleep assessment PD Sleep Scale (PDSS); Pain assessment King Parkinson's Pain Assessment (KPPS) and adverse events were recorded.

Eligibility Criteria:
Inclusion Criteria:

* Hoehn-YAHR classification is between 1 and 2；
* Have a primary school education or above and can read the scale used in this study;
* MoCA score between 20 and 24, mild cognitive impairment ;
* Aged between 30 and 80, regardless of gender；
* Voluntarily participate and sign informed consent.

Exclusion Criteria:

* patients with cerebrovascular accident, craniocerebral injury and other diseases affecting muscle tension;
* patients with serious mental disorders and cognitive disorders who cannot cooperate with assessment;
* patients with severe liver, kidney, heart dysfunction and severe physical disorders;
* Implanted devices such as pacemakers are installed inside the body;
* drug-induced Parkinson's syndrome or Parkinson's superposition syndrome;
* Have a history of epilepsy;
* Women during pregnancy and breastfeeding.
Collection of Biological Data With Potential Prognostic Relevance in Patients With MYELODYSPLASTIC SYNDROMES

The present study is designed to determine the mutational status of markers (TET2 and PLCb2, cytogenetic aberrations) together with methylation status of the above genes using bone marrow and matched buccal cell samples from MDS patients who necessitate to start a treatment (i.e. EPO, Lenalidomide, Azacytidine). All patients included in the study will be followed for at least 2 years.


Eligibility Criteria:
Inclusion Criteria:

* Written informed consent
* Patients diagnosed with MDS according to FAB, WHO and IPSS classifications
* All clinically treatable MDS patients with EPO or Lenalidomide or 5-Azacytidine;
* Hb \< 10 g/dL
* Age ≥ 18 years
* Gender: Male or Female
* Sufficient amount of biological samples for molecular studies

Exclusion Criteria:

* Age \<18 years
* Patients who do not require treatment on "watch and wait" strategy
* Insufficient amount of biological samples for molecular studies
Modified Water Vapor Thermal Therapy in Management of Patients With Large-volume Benign Prostatic Hyperplasia

Water vapor thermal therapy (Rezum) is a minimally invasive treatment for benign prostatic hyperplasia (BPH) that uses injections of sterile water vapor directly into the prostate for tissue ablation. Although Rezum is currently indicated for use in men with prostate sizes ≥30 and ≤80 ml, the guidelines offer no recommendation with regards to Rezum therapy for those with large-volume glands.

For prostates larger than 80ml, open or transurethral anatomical enucleation is recommended. Open prostatectomy has a higher risk of bleeding and slower postoperative recovery, with a higher probability of requiring blood transfusion. The incidence of urinary incontinence after transurethral enucleation ranges from 3.33% to 20%, possibly due to excessive traction and compression on the external urethral sphincter, leading to partial muscle fiber rupture. The rate of erectile dysfunction after enucleation is 8.82%, while retrograde ejaculation occurs in 6.37% of cases, especially for patients with larger prostates. Once these complications occur, they are often difficult to recover from and severely impact the patient's quality of life. In our center, the technique of Rezum has been further improved by incorporating ultrasound and MRI imaging guidance. The investigators design a reasonable and comprehensive ablation plan that ensures accurate positioning of enlarged prostate glands for complete and thorough ablation while ensuring efficacy and safety.

Eligibility Criteria:
Inclusion Criteria:

1. Male subjects ≥ 45 years of age who have obstructive symptoms secondary to BPH requiring invasive intervention.
2. IPSS score of ≥ 13.
3. Qmax: Peak flow rate ≤ 15 ml/sec.
4. Post-void residual (PVR) \< 300 ml.
5. Prostate volume between 80 to 120 ml.
6. Subject able to complete the study protocol in the opinion of the Principal Investigator.

Exclusion Criteria:

1. History of any illness or surgery that in the opinion of the Principal Investigator may confound the results of the study.
2. Any prior minimally invasive intervention or surgical intervention for the symptoms of BPH.
3. Currently enrolled in another clinical trial.
4. Confirmed or suspected malignancy of prostate or bladder.
5. Documented active urinary tract infection by culture or bacterial prostatitis.
6. Neurogenic bladder or sphincter abnormalities.
7. Urethral strictures, bladder neck contracture or muscle spasms.
8. Bleeding disorder (note that use of anti-platelet medication is not an exclusion criterion).
9. Subjects who are interested in maintaining fertility.
10. Significant urge incontinence.
11. Unable or unwilling to sign the Informed Consent Form.
12. Any cognitive disorder that interferes with or precludes a subject from directly and accurately communicating with the Principal Investigator regarding the study.
: Intravascular Injection Rates During Cervical Medial Branch Block

The purpose of this study is to compare using Toughy needle has an advantage of reducing intravascular injection rates during cervical medial branch block.

In previous reports, the use of Toughy needle was thought to reduce the incidence of intravascular injection as low as 2.9% during lumbar transforaminal injection.

Blunt needles with a pencil point tip, such as Whitacre needles, are not as sharp at their tip as are Quincke needles, which have bevels. Toughy or blunt needles may therefore be less likely to penetrate a vessel during a procedure. Hence, we postulated the incidence of intravenous uptake would be significantly lower using a Toughy needle than using a Quincke needle for lumbar medial branch block. To confirm the intravascular injection rates, we used the real time fluoroscopy after injection of contrast medium.

The goal of this study was to compare the incidence of intravascular injection rate betweeen Toughy and Quincke needles using real time fluoroscopy during cervical medial branch block

Eligibility Criteria:
Inclusion Criteria:

* facet joint arthropathy

Exclusion Criteria:

* allergy to local anesthetics or contrast medium
* pregnancy
* spine deformity
* neurologic abnormality
Biomarkers of Chronic Obstructive Pulmonary Disease

There are few studies about immunological explorations in COPD. Because of the complications of lung biopsies, analyses are generally made on blood samples instead of lung tissue. No study tried to classify COPD vs Asthma vs ACOS. The investigators wondered if there were differences in biomarkers between these groups. The investigators decided to open a pilot-study among COPD patients followed in Amiens-University Hospital. Each patient will be examined and a blood-test will be performed.


Eligibility Criteria:
Inclusion Criteria:

* BPCO patients
* ACOS patients
* asthmatic patient without BPCO

Exclusion Criteria:

* infection
* exacerbation
* immunosuppressive treatment
* immunosuppressive disease
Establishment of MRI Model for pTRG in Rectal Cancer With Establishment of

This study proposeto integrate a variety of imaging quantitative indicators to establish a new MRI-based tumor response regression(mrTRG) classification method. The accuracy of the established mrTRG classification method according pathology TRG(pTRG) will be tested. The ability of the established mrTRG classification method to predict prognosis will also be tested.

The study included two part: one is a retrospective single-center cohort for analyzing quantitative MRI factors associated with pTRG, from which a new MRI-based tumor response regression(mrTRG) classification method will be established. The other is a prospective multi-center cohort for testing the accuracy of the established mrTRG classification according to pTRG; and also for validating the established mrTRG classification associated with survival.

Eligibility Criteria:
Inclusion Criteria:

* biopsy-proved primary rectal cancer
* baseline MRI confirmed LARC (cT3 and/or cN+)
* scheduled to take neoadjuvant therapy
* receive baseline and preoperative pelvic MRI
* receive TME surgery after NAT
* have routine follow-up after the operation

Exclusion Criteria:

* history of malignancy or multiple primary cancers
* receive surgery directly without NAT
* don't receive TME surgery
* don't complete NAT
* simultaneous distant metastasis at the baseline diagnosis
* lack of baseline or preoperative pelvic MRI
* incomplete or unavailable pathological information
* lost to follow-up within three months after surgery (lost since the first follow-up visit)
Prenatal Dex Study

The classic form of 21-hydroxylase deficiency (prevalence 1/15,000) is the most common cause of congenital adrenal hyperplasia (CAH). This autosomic recessive disease is responsible for virilization of the external genitalia in girls through androgen hypersecretion during fetal life. Since 1984, the Lyon Pediatric Endocrinology group has proposed prenatal dexamethasone (DEX) for all fetuses at risk of CAH With the aim of preventing fetal androgen hypersecretion in affected girls and avoiding poor long-term results from reconstructive surgery. Prenatal DEX was used in Europe and the USA but its use was recently suspended: in 2007, a Swedish study conducted on 26 children treated with DEX in utero for a short period of time reported cognitive impairments. These data were not confirmed by an American study on the short-term DEX use, which showed potential cognitive impairments in CAH children exposed to DEX for long periods of time. These confusing and controversial results have caused the scientific community to question its position and have resulted in the suspension of the use of prenatal DEX with drastic consequences for CAH girls (virilization; genital surgery etc.). In this context, an evaluation of neuropsychological development under in utero DEX is essential to validate its indication for use during the prenatal period. This study will evaluate outcomes using prospective cognitive and emotional assessments. It will first focus on the unaffected children previously treated in utero in order to assess the adverse effects of the drug. The study will then assess the children with CAH for whom DEX could have beneficial effects.


Eligibility Criteria:
Inclusion Criteria:

Groups D+1, D+2, D-1 and D-2

* Male or female
* Patient with Congenital Adrenal Hyperplasia or sibling of a CAH patient
* Age: 6 to 15 years (at the time of inclusion)
* The subject's legal representatives have understood the information note/informed consent form, obtained answers to all their questions and have given signed, written, informed consent
* Subject with health insurance

Group D-3 (Schoolchildren)

* Male or female
* With no connection with Congenital Adrenal Hyperplasia
* Age: 6 to 15 years (at the time of inclusion)
* The subject's legal representatives have understood the information note/informed consent form, obtained answers to all their questions and have given signed, written, informed consent
* Subject with health insurance

Exclusion Criteria:

For all groups :

* Patient/Subject with another genetic disease
* Patient/Subject with known neuropsychology disease(s)
* Patient/Subject whose mother has received another treatment during her pregnancy with possible known adverse events on the neuropsychological development of the child
Effects of Face Mask Continuous Positive Airway Pressure Vs. Noninvasive Ventilation Vs. High-flow Nasal Oxygen on Intubation-free Survival in Acute Hypoxemic Respiratory Failure: the TRIPOD Randomized Clinical Trial

Acute hypoxemic respiratory failure (AHRF) is a common indication for admission to an intensive care unit (ICU), with mortality exceeding 50% in cases where invasive mechanical ventilation is needed. Therefore, assessment of the most adequate oxygen strategy to avoid intubation in patients with AHRF deserves consideration.Previous studies have indicated that non-invasive oxygenation strategies, including high-flow nasal oxygen (HFNO), helmet or face mask noninvasive ventilation (NIV), and continuous positive airway pressure (CPAP), are effective in preventing endotracheal intubation in adult patients with AHRF when compared to the standard oxygen therapy. However, the optimal non-invasive oxygenation strategies remain uncertain. This study aim to determine whether CPAP, compared with HFNC or NIV, increase the intubation-free survival during study period in patients with AHRF.


Eligibility Criteria:
Inclusion Criteria:

1. Age≥18 yrs;
2. A ratio of the partial pressure of arterial oxygen (PaO2) to the FiO2 of 300 mm Hg or less, or a ratio of pulse oximetry oxygen saturation (SpO2) to the FiO2 of 315 or less (SpO2≤97%) and the need for (1) noninvasive positive pressure ventilation with at least 5 cm H2O PEEP, or (2) high-flow nasal cannula at 30L/min or higher, or (3) standard oxygen with oxygen flow rate of at least 10 L/min;
3. Sign informed consent.

Exclusion Criteria:

1. Patients that have already received Continuous positive airway pressure, Noninvasive ventilation continuously for more than 24 hours before the screening visit.
2. Previous bout of mechanical ventilation during index hospitalization.
3. Exacerbation of chronic lung disease, including asthma or chronic obstructive pulmonary disease.
4. Moderate to severe cardiac insufficiency (New York Heart Association class \>II or left ventricular ejection fraction\<50%) or cardiogenic pulmonary edema.
5. Hemodynamic dysfunction, defined as vasopressor dose \> 0.3 µg/kg/min of norepinephrine-equivalent to maintain systolic blood pressure \> 90 mm Hg.
6. Impaired consciousness with a Glasgow coma score ≤ 12.
7. Patients with urgent need for intubation, including respiratory or cardiac arrest, respiratory pauses with loss of consciousness or gasping for air, severe hypoxemia defined as SpO2 lower than 90% despite maximal oxygen support.
8. Patients with contraindication to NIV according to the French consensus conference, patient refusal, cardiorespiratory arrest, coma, non-drained pneumothorax, unresolved vomiting, upper airway obstruction, hematemesis or severe facial trauma, thoracic or abdominal surgery in the previous 7 days.
9. A do-not-intubate order at time of inclusion.
10. Pregnancy.
A Randomized Trial of Cerclage Versus 17 α-Hydroxyprogesterone Caproate for Treatment of a Short Cervix

We hypothesized that weekly intramuscular injections of 17 hydroxyprogesterone caproate(17P) will reduce the number spontaneous preterm births prior to 35 weeks gestation when compared to cerclage therapy. The purpose of this study was to compare medical therapy with 17P to surgical therapy with transvaginal cerclage in patients with an ultrasound diagnosed short cervix and funnel in the mid-trimester.


Eligibility Criteria:
Inclusion Criteria:

* Ultrasonographic evidence of premature dilatation of the internal os
* Prolapse of the chorio-amniotic membranes into the endocervical canal
* Functional cervical length less than 25mm
* Exacerbation of these ultrasound findings with transfundal and/or suprapubic pressure

Exclusion Criteria:

* Any fetal chromosomal or structural anomaly
* Multiple gestation
* Known allergy to progesterone
* Ruptured membranes
* Vaginal bleeding
* Intra-amniotic infection (diagnosed clinically or by amniocentesis)
* Prolapse of endocervical membranes beyond the external cervical os
* Persistent uterine activity accompanied by cervical change
* Obstetrically indicated delivery.
Treatment of Polycythemia Vera With Gleevec

The purpose of this research study is to evaluate the safety and effectiveness of patients with Polycythemia Vera treated with Gleevec.

Phlebotomy is a standard temporizing treatment for Polycythemia Vera. Performing repeated phlebotomies may lead to iron deficiency and can contribute to a rising platelet count. This may create additional problems, such as clots particularly in patients older than 50. There is reason to believe that the use of Gleevec may cause a decrease in the activity of the marrow so that patients may not require as many or any phlebotomies. Thus, spleen function may possibly improve by decreasing in size and patients' platelet counts may also improve.

Eligibility Criteria:
Inclusion Criteria:

* Patients have diagnosis of Polycythemia Vera (PV). Patients may have newly diagnosed PV.
* Patients may have previously interferon-alfa treated PV with documented resistance, refractoriness or intolerance to interferon-alfa.
* Patients may have PV with inadequate control on hydroxyurea.
* Performance status of 0, 1, or 2
* Adequate end organ function, defined as the following:

  1. total bilirubin \<1.5 x upper limit of the normal range (ULN)
  2. SGOT (AST) and SGPT (ALT) \< 2.5 x ULN
  3. creatinine \< 1.5 x ULN
  4. ANC \> 1.5 x 109/L
* Written voluntary informed consent.

Exclusion Criteria:

* Female patients who are pregnant or breast-feeding.
* Patients receiving busulfan within 6 weeks of Study Day 1.
* Patients receiving interferon-alpha within 4 weeks of Study Day 1.
* Patients receiving hydroxyurea within 2 weeks of Study Day 1.
* Patients with Grade III or IV cardiac problems as defined by the New York Heart Association Criteria.
* Patients with a history of non-compliance to medical regimens or who are considered potentially unreliable.
* Patients previously treated with Gleevec.
* Serum erythropoietin level \> or = 25 units/microliter
* Abnormal O2 saturation (by pulse oximetry) or arterial pO2 (by arterial blood gas).